NIH × Congenital Abnormalities × Classical hematology × Clear all Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
2,000 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Phase 1 Completed
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Phase 1 Completed
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
Phase 2 Completed
52 enrolled
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase 1 Completed
60 enrolled
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Phase 2 Completed
74 enrolled
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
40 enrolled
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase 1 Completed
40 enrolled
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Phase 1 Completed
35 enrolled
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
Phase 2 Completed